应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
09926 康方生物
未开盘 11-17 16:08:15
61.900
-2.200
-3.43%
最高
66.700
最低
61.850
成交量
1,870万
今开
63.000
昨收
64.100
日振幅
7.57%
总市值
582.48亿
流通市值
582.48亿
总股本
9.41亿
成交额
11.80亿
换手率
1.99%
流通股本
9.41亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
康方生物(09926.HK)拟新增不超过2亿港元在公开市场购买股份
智通财经 · 11-17 21:36
康方生物(09926.HK)拟新增不超过2亿港元在公开市场购买股份
康方生物(09926)获批动用不超2亿港元于公开市场购股
公告速递 · 11-17 21:35
康方生物(09926)获批动用不超2亿港元于公开市场购股
康方生物(09926)斥资约1,600万港元回购25万股
公告速递 · 11-17 21:10
康方生物(09926)斥资约1,600万港元回购25万股
康方生物(09926):受托人以总代价约1600万港元购买25万股公司股份
智通财经 · 11-17 21:02
康方生物(09926):受托人以总代价约1600万港元购买25万股公司股份
异动解读|康方生物盘中上涨3.28%,回购释放信心后股价反弹
行情直击 · 11-17 09:42
异动解读|康方生物盘中上涨3.28%,回购释放信心后股价反弹
康方生物股价暴跌22%:依沃西美国上市失利 夏瑜称是创业14年来最沮丧的一次
市场资讯 · 11-16 22:36
康方生物股价暴跌22%:依沃西美国上市失利 夏瑜称是创业14年来最沮丧的一次
康方生物:斥资约2100万港元回购34万股
财中社 · 11-16 19:59
康方生物:斥资约2100万港元回购34万股
康方生物核心产品在美首个上市申请被拒,中国创新药的后半程如何跑通?
每日经济新闻 · 11-16 19:37
康方生物核心产品在美首个上市申请被拒,中国创新药的后半程如何跑通?
康方生物(09926.HK):受托人根据2021年受限制股份单位计划购买33.6万股
智通财经 · 11-16 19:10
康方生物(09926.HK):受托人根据2021年受限制股份单位计划购买33.6万股
康方生物(09926)受托人于公开市场购入33.6万股 涉资约2,100万港元
公告速递 · 11-16 19:06
康方生物(09926)受托人于公开市场购入33.6万股 涉资约2,100万港元
依沃西美国上市遭拒,康方生物迎来“最沮丧”时刻
北京商报 · 11-16 18:46
依沃西美国上市遭拒,康方生物迎来“最沮丧”时刻
大行评级|花旗:降康方生物目标价至163港元,下调收入及纯利预测
中金财经 · 11-16 16:35
大行评级|花旗:降康方生物目标价至163港元,下调收入及纯利预测
大行评级|杰富瑞:维持康方生物“买入”评级,市场对HARMONi-3审慎预期创造上行空间
格隆汇 · 11-16 14:20
大行评级|杰富瑞:维持康方生物“买入”评级,市场对HARMONi-3审慎预期创造上行空间
大行评级|野村:下调康方生物目标价至94港元,评级降至“中性”
格隆汇 · 11-16 13:12
大行评级|野村:下调康方生物目标价至94港元,评级降至“中性”
康方生物(09926):股价异常波动 不知悉任何导致有关价格波动的原因
智通财经 · 11-16 12:32
康方生物(09926):股价异常波动 不知悉任何导致有关价格波动的原因
康方生物盘中跌超三成:核心抗癌药在美国未能获批
澎湃新闻 · 11-16 12:24
康方生物盘中跌超三成:核心抗癌药在美国未能获批
康方生物(09926)发布澄清公告:FDA向合作药物发出完整回函 目前无其他需披露信息
公告速递 · 11-16 12:16
康方生物(09926)发布澄清公告:FDA向合作药物发出完整回函 目前无其他需披露信息
依沃西“闯美”首战失利,康方生物一度下挫30%!港股通创新药板块延续调整,520880标的指数跌逾3.6%
新浪基金 · 11-16 11:11
依沃西“闯美”首战失利,康方生物一度下挫30%!港股通创新药板块延续调整,520880标的指数跌逾3.6%
大行评级|瑞银:康方生物合作伙伴就ivonescimab联合化疗BLA接获FDA完整回应信属轻微负面,维持“买入”评级
格隆汇 · 11-16 10:59
大行评级|瑞银:康方生物合作伙伴就ivonescimab联合化疗BLA接获FDA完整回应信属轻微负面,维持“买入”评级
康方生物盘初暴跌近32% 核心产品依沃西单抗美国上市申请遭FDA拒绝
金融界 · 11-16 10:33
康方生物盘初暴跌近32% 核心产品依沃西单抗美国上市申请遭FDA拒绝
加载更多
公司概况
公司名称:
康方生物
所属市场:
SEHK
上市日期:
--
主营业务:
康方生物科技(开曼)有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。该公司的产品主要包括有用于肿瘤领域的开坦尼(卡度尼利,PD-1/CTLA-4)、依达方(依沃西,PD-1/VEGF)、莱法利(AK117,CD47)、普络西(AK109,VEGFR-2)、安尼可(派安普利,PD-1)、科泰莱(塔戈利单抗,PD-L1)和用于代谢及自免领域的伊喜宁(伊努西单抗,PCSK9)、爱达罗(依若奇单抗,IL-12/IL-23)、古莫奇单抗(AK111,IL-17)。
发行价格:
--
{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":61.9,"timestamp":1794902895008,"preClose":64.1,"halted":0,"volume":18702927,"delay":0,"changeRate":-0.034321372854914135,"floatShares":941000000,"shares":941000000,"eps":-1.450868453966261,"marketStatus":"未开盘","change":-2.2,"latestTime":"11-17 16:08:15","open":63,"high":66.7,"low":61.85,"amount":1180104565,"amplitude":0.075663,"askPrice":61.95,"askSize":31000,"bidPrice":61.9,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":-1.244560886998823,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794965400000},"marketStatusCode":0,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":64.1,"openAndCloseTimeList":[[1794879000000,1794888000000],[1794891600000,1794902400000]],"volumeRatio":0.9230898184952445,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.2456,"impliedVolPercentile":0.0683},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"2684985190","title":"康方生物(09926.HK)拟新增不超过2亿港元在公开市场购买股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2684985190","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684985190?lang=zh_cn&edition=full","pubTime":"2026-11-17 21:36","pubTimestamp":1794922567,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","LU0634319403.HKD","LU0348783233.USD","LU0417516902.SGD","IE00B543WZ88.USD","LU1720050803.USD","LU0348827113.USD","LU0561508036.HKD","BK1574","IE00BPRC5H50.USD","LU1794554557.SGD","LU0417516738.SGD","LU0540923850.HKD","LU2399975544.HKD","09926","LU0348767384.USD","LU0417516571.SGD","LU2778985437.USD","LU0348784397.USD","LU0348735423.USD","LU2488822045.USD","LU1961090484.USD","KURE","LU0348766576.USD","LU0348825331.USD","LU2476274720.SGD","LU2476274308.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136296660","title":"康方生物(09926)获批动用不超2亿港元于公开市场购股","url":"https://stock-news.laohu8.com/highlight/detail?id=1136296660","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136296660?lang=zh_cn&edition=full","pubTime":"2026-11-17 21:35","pubTimestamp":1794922553,"startTime":"0","endTime":"0","summary":"康方生物科技(开曼)有限公司11月17日公告称,公司董事会已批准新增不超过2亿港元用于在公开市场购买公司股份。该笔资金将由公司2021年受限制股份单位计划的受托人执行,用于在二级市场内进行股份购入。公告指出,董事会认为当前股价未能充分反映公司的内在价值及增长潜力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169293191","title":"康方生物(09926)斥资约1,600万港元回购25万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1169293191","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169293191?lang=zh_cn&edition=full","pubTime":"2026-11-17 21:10","pubTimestamp":1794921033,"startTime":"0","endTime":"0","summary":"2026年11月17日,康方生物(09926)发布自愿公告称,其受托人于公开市场以总代价约1,600万港元购入公司股份250,000股。\n公司董事会表示,本次购股款项来自现有可用现金资源。公告称,此举反映公司对业务及未来前景的信心。\n截至公告日期,公司董事会由8名成员组成,包括主席兼执行董事夏瑜博士等。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684498335","title":"康方生物(09926):受托人以总代价约1600万港元购买25万股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2684498335","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684498335?lang=zh_cn&edition=full","pubTime":"2026-11-17 21:02","pubTimestamp":1794920553,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康方生物(09926)发布公告,于2026年11月17日,受托人于公开市场上以总代价约1600万港元购买25万股公司股份。公司董事会认为,购买股份反映公司对业务展望及未来前景充满信心。购买股份由公司现有可用现金资源拨付。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1524654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0540923850.HKD","LU2488822045.USD","BK1161","LU0348766576.USD","LU0561508036.HKD","KURE","BK1574","LU2399975544.HKD","LU0348784397.USD","LU1961090484.USD","LU0348825331.USD","IE00BPRC5H50.USD","LU2476274720.SGD","LU0634319403.HKD","LU1794554557.SGD","09926","LU1720050803.USD","LU2476274308.USD","IE00B5MMRT66.SGD","LU0417516738.SGD","LU0348735423.USD","IE00B543WZ88.USD","LU2778985437.USD","LU0348767384.USD","LU0348783233.USD","LU0348827113.USD","LU0417516571.SGD","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196272672","title":"异动解读|康方生物盘中上涨3.28%,回购释放信心后股价反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1196272672","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196272672?lang=zh_cn&edition=full","pubTime":"2026-11-17 09:42","pubTimestamp":1794879752,"startTime":"0","endTime":"0","summary":"11月17日,康方生物盘中上涨3.28%,报66.2港元,成交额2.1亿港元。消息面上,公司此前公告受托人于11月16日在公开市场购入约33.6万股,涉资约2100万港元,资金来自现有可用现金;董事会表示,此举反映对业务展望及未来前景充满信心。此前依沃西单抗美国上市申请收到FDA完整回应函,曾引发股价大跌并拖累合作方Summit夜盘重挫。公司其后澄清目前运营正常,且管理层紧急沟通投资者,回购举措成为短线情绪修复的重要支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康方生物回购释放信心,股价应声反弹","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683643618","title":"康方生物股价暴跌22%:依沃西美国上市失利 夏瑜称是创业14年来最沮丧的一次","url":"https://stock-news.laohu8.com/highlight/detail?id=2683643618","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683643618?lang=zh_cn&edition=full","pubTime":"2026-11-16 22:36","pubTimestamp":1794839760,"startTime":"0","endTime":"0","summary":"依沃西美国上市失利消息公布后,Summit股价夜盘暴跌20%,作为重要合作伙伴的康方生物自然难以幸免。夏瑜称是创业14年来最沮丧的一次康方生物创始人、CEO夏瑜博士昨日紧急举行电话会议,安抚投资者。夏瑜说,这个消息令人非常沮丧,这也是康方生物成立14年以来,自己感到最沮丧的一次。康方生物2026年上半年毛利为13.4亿元,2025年上半年为11.21亿元。康方生物2026年上半年期内亏损为4.47亿元,上年同期的期内亏损为5.88亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-11-16/doc-iniyxynx5891700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2476274308.USD","LU0348766576.USD","LU0348827113.USD","161022","LU0348735423.USD","LU0540923850.HKD","LU1720050803.USD","LU2399975544.HKD","LU0417516571.SGD","LU2488822045.USD","LU0348825331.USD","BK1574","LU0348784397.USD","LU0417516902.SGD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","09926","IPOS","LU0348767384.USD","LU2476274720.SGD","LU0634319403.HKD","LU0348783233.USD","LU0561508036.HKD","LU0417516738.SGD","LU1961090484.USD","IE00B543WZ88.USD","LU1794554557.SGD","BK1161","LU2778985437.USD","KURE"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2683190456","title":"康方生物:斥资约2100万港元回购34万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2683190456","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683190456?lang=zh_cn&edition=full","pubTime":"2026-11-16 19:59","pubTimestamp":1794830390,"startTime":"0","endTime":"0","summary":"11月16日,康方生物(09926)发布公告,受托人今日在公开市场上以总价约2100万港元购买34万股。董事会认为,回购股份反映公司对业务展望及未来前景充满信心。此次回购股份的资金来源于公司现有可用现金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611163931997966.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611163931997966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1961090484.USD","BK1574","LU2476274720.SGD","LU0348766576.USD","LU0348735423.USD","LU0348784397.USD","LU2476274308.USD","IE00B5MMRT66.SGD","LU2399975544.HKD","LU0348767384.USD","BK1161","LU2488822045.USD","LU0348783233.USD","KURE","LU2778985437.USD","LU0417516902.SGD","LU0348827113.USD","LU0417516571.SGD","LU1794554557.SGD","IE00B543WZ88.USD","LU1720050803.USD","LU0417516738.SGD","IE00BPRC5H50.USD","LU0561508036.HKD","LU0634319403.HKD","LU0348825331.USD","09926","LU0540923850.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683616178","title":"康方生物核心产品在美首个上市申请被拒,中国创新药的后半程如何跑通?","url":"https://stock-news.laohu8.com/highlight/detail?id=2683616178","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683616178?lang=zh_cn&edition=full","pubTime":"2026-11-16 19:37","pubTimestamp":1794829058,"startTime":"0","endTime":"0","summary":"11月15日晚上9点半,康方生物(HK09926)电话会准时开始。这场临时举行的电话会,始于依沃西在美国的首次上市申请未获得批准。美国食品药品监督管理局(FDA)认为,尽管HARMONi研究达到无进展生存期主要终点,但总生存期未显示统计学显著改善。康方生物电话会开始不久,董事长夏瑜表示,“这个结果我们所有人都很沮丧,这也是公司成立14年以来,让我个人最为沮丧的一次。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611163931986819.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611163931986819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0540923850.HKD","IE00BPRC5H50.USD","LU0417516902.SGD","LU0417516738.SGD","IPOS","LU2476274308.USD","LU1794554557.SGD","LU0561508036.HKD","LU0348827113.USD","LU0348784397.USD","LU1720050803.USD","09926","LU2476274720.SGD","IE00B543WZ88.USD","LU0417516571.SGD","LU0348766576.USD","LU1961090484.USD","KURE","BK1161","LU2778985437.USD","BK1574","LU0348825331.USD","LU0348767384.USD","LU2488822045.USD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU2399975544.HKD","LU0348783233.USD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683461555","title":"康方生物(09926.HK):受托人根据2021年受限制股份单位计划购买33.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2683461555","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683461555?lang=zh_cn&edition=full","pubTime":"2026-11-16 19:10","pubTimestamp":1794827427,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0540923850.HKD","IE00BPRC5H50.USD","LU0561508036.HKD","LU2476274308.USD","LU2476274720.SGD","LU1720050803.USD","LU2488822045.USD","IE00B5MMRT66.SGD","BK1161","09926","LU1794554557.SGD","LU0348767384.USD","LU0348766576.USD","LU0417516571.SGD","KURE","LU0348825331.USD","LU0348783233.USD","LU0348735423.USD","LU1961090484.USD","LU0348827113.USD","LU2778985437.USD","BK1574","LU0417516738.SGD","LU2399975544.HKD","IE00B543WZ88.USD","LU0348784397.USD","LU0417516902.SGD","LU0634319403.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113640002","title":"康方生物(09926)受托人于公开市场购入33.6万股 涉资约2,100万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1113640002","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113640002?lang=zh_cn&edition=full","pubTime":"2026-11-16 19:06","pubTimestamp":1794827170,"startTime":"0","endTime":"0","summary":"康方生物科技(开曼)有限公司11月16日发布自愿公告称,其2021年限制性股份单位计划的受托人已于2026年11月16日在公开市场以总代价约2,100万港元购入公司股份,共计336,000股。公告指出,本次购股所需资金来自公司现有可用现金资源。董事会表示,此举反映公司对业务及未来前景充满信心。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683107613","title":"依沃西美国上市遭拒,康方生物迎来“最沮丧”时刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2683107613","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683107613?lang=zh_cn&edition=full","pubTime":"2026-11-16 18:46","pubTimestamp":1794825965,"startTime":"0","endTime":"0","summary":"11月16日,港股康方生物遭遇重挫,一度跌超30%。股价大跌源于前一天的一则利空消息,北京时间11月15日,康方生物海外合作伙伴SummitTherapeutics发布公告称,美国食品药品监督管理局(FDA)未批准依沃西(ivonescimab)上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611163931923437.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611163931923437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0348735423.USD","LU2778985437.USD","LU0417516902.SGD","LU0561508036.HKD","LU0417516571.SGD","BK1574","IE00BPRC5H50.USD","BK1161","LU0540923850.HKD","LU1720050803.USD","LU1961090484.USD","LU0348827113.USD","LU0417516738.SGD","IE00B543WZ88.USD","LU0634319403.HKD","LU0348766576.USD","LU0348784397.USD","09926","IE00B5MMRT66.SGD","LU0348825331.USD","LU1794554557.SGD","KURE","LU2399975544.HKD","IPOS","LU0348767384.USD","LU2476274720.SGD","LU0348783233.USD","LU2476274308.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683691286","title":"大行评级|花旗:降康方生物目标价至163港元,下调收入及纯利预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2683691286","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683691286?lang=zh_cn&edition=full","pubTime":"2026-11-16 16:35","pubTimestamp":1794818104,"startTime":"0","endTime":"0","summary":"该行指出,FDA决定将延迟潜在海外特许权收入,并削弱ivonescimab美国商业化的近期限能见度。该行因此将2027及2028年财政年度收入预测分别下调1%及1%,纯利预测分别下调12%及3%,目标价由171港元降至163港元,维持“买入”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20261116/32424389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["09926","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683698586","title":"大行评级|杰富瑞:维持康方生物“买入”评级,市场对HARMONi-3审慎预期创造上行空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2683698586","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683698586?lang=zh_cn&edition=full","pubTime":"2026-11-16 14:20","pubTimestamp":1794810057,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1794554557.SGD","IE00BPRC5H50.USD","LU0417516902.SGD","BK1161","LU0348783233.USD","LU2488822045.USD","LU2476274308.USD","KURE","LU0540923850.HKD","09926","IE00B5MMRT66.SGD","LU0348766576.USD","LU0348827113.USD","IE00B543WZ88.USD","LU0561508036.HKD","LU2399975544.HKD","BK1574","LU0348784397.USD","LU1961090484.USD","LU0417516738.SGD","LU0348825331.USD","LU1720050803.USD","LU2778985437.USD","LU2476274720.SGD","LU0348735423.USD","LU0634319403.HKD","LU0417516571.SGD","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683667176","title":"大行评级|野村:下调康方生物目标价至94港元,评级降至“中性”","url":"https://stock-news.laohu8.com/highlight/detail?id=2683667176","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683667176?lang=zh_cn&edition=full","pubTime":"2026-11-16 13:12","pubTimestamp":1794805926,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0348735423.USD","BK1161","09926","LU2778985437.USD","LU1720050803.USD","LU0540923850.HKD","LU2476274720.SGD","KURE","LU0634319403.HKD","LU1794554557.SGD","IE00B5MMRT66.SGD","BK1574","LU0348766576.USD","LU0348825331.USD","LU0348783233.USD","LU2476274308.USD","LU0417516738.SGD","LU0561508036.HKD","LU2488822045.USD","LU0348827113.USD","IE00B543WZ88.USD","LU2399975544.HKD","LU0417516571.SGD","IE00BPRC5H50.USD","LU0348767384.USD","LU0348784397.USD","LU0417516902.SGD","LU1961090484.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683662092","title":"康方生物(09926):股价异常波动 不知悉任何导致有关价格波动的原因","url":"https://stock-news.laohu8.com/highlight/detail?id=2683662092","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683662092?lang=zh_cn&edition=full","pubTime":"2026-11-16 12:32","pubTimestamp":1794803565,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康方生物(09926)发布公告,本公司注意到Summit Therapeutics Inc. (NASDAQ: SMMT)于2026年11月15日刊发的新闻稿,内容有关其就基于HARMONi研究提交的依沃西单抗(ivonescimab)生物制品上市许可申请收到美国食品药物管理局发出的完整回应函件(CRL)。经作出在有关情况下就本公司而言属合理的查询后,本公司确认,除上述CRL可能导致本公司股份价格出现异常波动外,董事会并不知悉任何导致有关价格波动的原因,亦不知悉任何为避免本公司证券出现虚假市场而必须公布的资料,或任何根据《证券及期货条例》第XIVA部须予披露的内幕消息。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1523516.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274308.USD","LU2778985437.USD","IE00B543WZ88.USD","LU1794554557.SGD","LU1961090484.USD","IE00BPRC5H50.USD","LU0417516902.SGD","LU0561508036.HKD","LU0540923850.HKD","LU0348783233.USD","BK1574","LU0348827113.USD","LU1720050803.USD","LU2488822045.USD","LU0417516571.SGD","LU0348767384.USD","BK1161","LU0348825331.USD","LU2399975544.HKD","09926","KURE","LU0348766576.USD","LU0417516738.SGD","LU0348784397.USD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU2476274720.SGD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683667337","title":"康方生物盘中跌超三成:核心抗癌药在美国未能获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2683667337","media":"澎湃新闻","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683667337?lang=zh_cn&edition=full","pubTime":"2026-11-16 12:24","pubTimestamp":1794803056,"startTime":"0","endTime":"0","summary":"11月16日,康方生物(9926.HK)开盘即跌,盘中最高跌超31%,截至午盘跌23.27%。消息面上,当地时间11月15日,康方生物的美国合作伙伴Summit发布消息称,ivonescimab未能获得美国食品药品监督管理局(FDA)的批准,原因是FDA认定,在没有统计学显著的总生存期(OS)改善的情况下,无法确立实质性的有效性证据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611163931669569.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611163931669569.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","LU2778985437.USD","LU0348783233.USD","LU0417516738.SGD","LU2476274308.USD","IE00B5MMRT66.SGD","LU0540923850.HKD","LU0348784397.USD","LU1794554557.SGD","LU0348827113.USD","LU0634319403.HKD","LU1720050803.USD","LU0561508036.HKD","LU2488822045.USD","LU0348735423.USD","IE00B543WZ88.USD","LU2399975544.HKD","LU0348766576.USD","BK1161","LU0348767384.USD","09926","CANC","LU1961090484.USD","LU2476274720.SGD","KURE","LU0417516571.SGD","IE00BPRC5H50.USD","LU0348825331.USD","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197659597","title":"康方生物(09926)发布澄清公告:FDA向合作药物发出完整回函 目前无其他需披露信息","url":"https://stock-news.laohu8.com/highlight/detail?id=1197659597","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197659597?lang=zh_cn&edition=full","pubTime":"2026-11-16 12:16","pubTimestamp":1794802599,"startTime":"0","endTime":"0","summary":"2026年11月16日,康方生物科技(开曼)有限公司根据香港联交所《上市规则》第13.10条要求发布澄清公告,回应因其合作伙伴 Summit Therapeutics Inc.收到美国食品药物管理局就依沃西单抗生物制品上市许可申请发出的完整回应函件而引发的股价波动。公告进一步强调,康方生物的运营及业务目前维持正常,董事会将持续关注事件进展,并在必要时依据相关法规及时履行信息披露义务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683664522","title":"依沃西“闯美”首战失利,康方生物一度下挫30%!港股通创新药板块延续调整,520880标的指数跌逾3.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2683664522","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683664522?lang=zh_cn&edition=full","pubTime":"2026-11-16 11:11","pubTimestamp":1794798660,"startTime":"0","endTime":"0","summary":"康方生物依沃西美国上市失利,股价剧烈波动。11月16日,康方生物跳空低开,一度狂泻逾30%,截至发稿跌逾23%,创近1年半新低,前期“FDA审批博弈”定价被一次性抹去。所在港股通创新药板块大面积飘绿,翰森制药、科伦博泰生物、三生制药等权重股均跌逾2%,港股通创新药ETF华宝标的指数跌超3.6%。逢低关注创新药,关注T+0交易利器:港股通创新药ETF华宝:标的指数100%布局创新药研发类公司,7成仓位押注创新药研发龙头。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-11-16/doc-iniywwze5763526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0540923850.HKD","MEDX","159992","BK1574","LU2476274308.USD","BK1161","KURE","LU0348783233.USD","LU2399975544.HKD","LU2778985437.USD","FLHK","LU1961090484.USD","LU0348735423.USD","LU0417516738.SGD","LU0348784397.USD","IBBQ","LU2476274720.SGD","06978","LU0348767384.USD","LU0561508036.HKD","LU0634319403.HKD","LU0348766576.USD","IE00B543WZ88.USD","LNGR","LU0348825331.USD","LU0417516571.SGD","520880","IE00BPRC5H50.USD","09926","LU0348827113.USD","LU1794554557.SGD","LU1720050803.USD","LU0417516902.SGD","LU2488822045.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683661202","title":"大行评级|瑞银:康方生物合作伙伴就ivonescimab联合化疗BLA接获FDA完整回应信属轻微负面,维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2683661202","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683661202?lang=zh_cn&edition=full","pubTime":"2026-11-16 10:59","pubTimestamp":1794797950,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BPRC5H50.USD","LU0417516738.SGD","LU2399975544.HKD","LU0561508036.HKD","LU0417516571.SGD","LU0348827113.USD","LU0348766576.USD","LU2476274308.USD","LU2778985437.USD","KURE","LU1961090484.USD","LU0348735423.USD","09926","LU0348783233.USD","LU0634319403.HKD","LU0417516902.SGD","LU0348784397.USD","LU2488822045.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU0348825331.USD","LU2476274720.SGD","LU1720050803.USD","BK1574","LU0540923850.HKD","LU1794554557.SGD","LU0348767384.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683066990","title":"康方生物盘初暴跌近32% 核心产品依沃西单抗美国上市申请遭FDA拒绝","url":"https://stock-news.laohu8.com/highlight/detail?id=2683066990","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683066990?lang=zh_cn&edition=full","pubTime":"2026-11-16 10:33","pubTimestamp":1794796403,"startTime":"0","endTime":"0","summary":"11月16日港股盘初,$康方生物$股价大幅跳水,跌幅一度扩大至近32%,报56.1港元,创2025年2月以来新低。消息面上,康方生物海外合作伙伴$Summit$ $Therapeutics$披露,$美国食品$药品监督管理局已就依沃西单抗联合化疗用于经EGFR-TKI治疗进展的非鳞状非小细胞肺癌的上市申请发出完整回复函,该申请暂未获批。此次CRL意味着该核心产品在美国的商业化进程遭遇实质性延后,后续里程碑款项及销售分成的兑现节奏亦面临不确定性。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/11/16094859152641.shtml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":-0.3053},{"period":"1month","weight":-0.322},{"period":"3month","weight":-0.3068},{"period":"6month","weight":-0.4842},{"period":"1year","weight":-0.4673},{"period":"ytd","weight":-0.4522}],"compareEarnings":[{"period":"1week","weight":-0.0427},{"period":"1month","weight":-0.0281},{"period":"3month","weight":-0.0779},{"period":"6month","weight":-0.074},{"period":"1year","weight":-0.109},{"period":"ytd","weight":-0.0828}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技(开曼)有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。该公司的产品主要包括有用于肿瘤领域的开坦尼(卡度尼利,PD-1/CTLA-4)、依达方(依沃西,PD-1/VEGF)、莱法利(AK117,CD47)、普络西(AK109,VEGFR-2)、安尼可(派安普利,PD-1)、科泰莱(塔戈利单抗,PD-L1)和用于代谢及自免领域的伊喜宁(伊努西单抗,PCSK9)、爱达罗(依若奇单抗,IL-12/IL-23)、古莫奇单抗(AK111,IL-17)。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":0.006875},{"month":4,"riseRate":0.833333,"avgChangeRate":0.041517},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.021305},{"month":6,"riseRate":0.571429,"avgChangeRate":0.077852},{"month":7,"riseRate":0.571429,"avgChangeRate":0.084887},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.012805},{"month":9,"riseRate":0.571429,"avgChangeRate":0.060911},{"month":10,"riseRate":0.428571,"avgChangeRate":0.003706},{"month":11,"riseRate":0.857143,"avgChangeRate":0.053249},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}